A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors.

被引：0
|
作者：
Dela Cruz, Filemon S.
Fox, Elizabeth
Muscal, Jodi Ann
Kirov, Ivan
Geller, James I.
DuBois, Steven G.
Kim, AeRang
Croop, James
Laetsch, Theodore Willis
Minard, Charles G.
Liu, Xiaowei
Weigel, Brenda
Okpara, Chinyere E.
Huang, Jie
Dutta, Lea
Aluri, Jagadeesh
Bender, Julia Lynne Glade
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] CHOC Childrens Hosp, Orange, CA USA
[5] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[6] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
[7] Harvard Med Sch, Boston, MA 02115 USA
[8] Childrens Natl Hosp, Washington, DC USA
[9] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[11] Childrens Hlth, Dallas, TX USA
[12] Childrens Oncol Grp, Monrovia, CA USA
[13] Univ Minnesota, Minneapolis, MN USA
[14] Eisai Ltd, Hatfield, Herts, England
[15] Eisai Inc, Woodcliff Lake, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10527
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] A PHASE I STUDY ON CABOZANTINIB MONOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT AND/OR REFRACTORY SOLID TUMORS (CAMEL STUDY)
    Nakajima, Miho
    Tao, Kayoko
    Kimura, Toshimi
    Ogawa, Chitose
    Arakawa, Ayumu
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [33] Single-agent dose-finding cohort of a phase 1/2 study of lenvatinib (LEN) in children and adolescents with refractory or relapsed solid tumors.
    Gaspar, Nathalie
    Melcon, Maria Soledad Gallego
    Venkatramani, Rajkumar
    Bielack, Stefan S.
    Casanova, Michela
    Locatelli, Franco
    Thebaud, Estelle
    Rigaud, Charlotte
    Abbou, Samuel
    Gambart, Marion
    Morland, Bruce
    Aerts, Isabelle
    Kraljevic, Silvija
    Li, Di
    Maniar, Hina
    Hayato, Seiichi
    Dutcus, Corina E.
    Hewson, Quentin Campbell
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Phase 1 study of abemaciclib in children with recurrent and refractory solid tumors including malignant brain tumors
    Cash, Thomas
    Aguilera, Dolly
    Macy, Margaret E.
    Hoffman, Lindsey
    Dorris, Kathleen
    McCracken, Courtney
    Hanberry, Bradley
    Castellino, Robert
    MacDonald, Tobey
    Wetmore, Cynthia
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [35] Updated Entrectinib Data in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including Primary CNS Tumors
    Miyachi, Mitsuru
    Desai, Ami
    Robinson, Giles
    Basu, Ellen
    Foster, Jennifer
    Gauvain, Karen
    Sabnis, Amit
    Gajjar, Amar
    PEDIATRIC BLOOD & CANCER, 2020, 67
  • [36] ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS
    Robinson, Giles
    Desai, Ami
    Basu, Ellen
    Foster, Jennifer
    Gauvain, Karen
    Sabnis, Amit
    Shusterman, Suzanne
    Macy, Margaret
    Mease, Luke
    Yoon, Janet
    Cash, Thomas
    Abdelbaki, Mohamed
    Nazemi, Kellie
    Pratilas, Christine
    Weiss, Brian
    Chohan, Saibah
    Cardenas, Alison
    Hutchinson, Katherine
    Bergthold, Guillaume
    Gajjar, Amar
    NEURO-ONCOLOGY, 2020, 22 : 344 - 344
  • [37] Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
    Robinson, Giles W.
    Gajjar, Amar J.
    Gauvain, Karen Marie
    Basu, Ellen M.
    Macy, Margaret E.
    Maese, Luke Devon
    Sabnis, Amit J.
    Foster, Jennifer Haunani
    Shusterman, Suzanne
    Yoon, Janet
    Weiss, Brian D.
    Abdelbaki, Mohamed
    Farid-Kapadia, Mufiza
    Meneses-Lorente, Georgina
    Cardenas, Alison
    Hutchinson, Katherine
    Bergthold, Guillaume
    Maneval, Edna Chow
    Fox, Elizabeth
    Desai, Ami Vijay
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN plus EVE in patients with metastatic renal cell carcinoma
    Lee, C-H.
    Motzer, R. J.
    Glen, H.
    Michaelson, M. D.
    Larkin, J.
    Minoshima, Y.
    Kanekiyo, M.
    Dairiki, R.
    Sachdev, P.
    Dutcus, C. E.
    Funahashi, Y.
    Voss, M. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Phase I study of gemcitabine plus bortezomib in elderly patients with solid tumors.
    Bommakanti, Satya
    Gada, Purvi
    Dudek, Arkadiusz
    CANCER RESEARCH, 2009, 69
  • [40] Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.
    Tsai, Hui-Jen
    Chiang, Nai-Jung
    Shiah, Her-Shyong
    Chang, Kwang-Yu
    Su, Wu-Chou
    Chang, Jang-Yang
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345